Compare ADMA Biologics Inc (ADMA) vs Nike Inc (NKE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Nike Inc — how do they compare? ADMA Biologics Inc trades at $9.76 (market cap $2.19B), while Nike Inc trades at $40.72 (market cap $60.10B). The key difference: Nike Inc is far larger — about 27.4× ADMA Biologics Inc's market cap, and Nike Inc pays a 4.05% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | NKE | |
|---|---|---|
Market Cap | $2.19B | $60.10B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $79.17 |
52-Week Low | $7.60 | $40.51 |
Enterprise Value | $2.26B | $62.10B |
Volume | — | 8,887,180 |
Dividend Yield | — | 4.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.78, up 0.31% today, with a bullish technical signal from moving averages and strong fundamentals including a 32.98% net income margin and 41.9% ROE. Recent earnings show a mix of beats and misses, with Q3 2026 EPS expected at $0.19. The stock faces headwinds from multiple class-action lawsuits alleging securities fraud, as reported by news outlets in August 2026.
Outlook is cautiously optimistic due to robust profitability and analyst support, but legal risks and recent earnings volatility pose challenges. Investment opportunity hinges on legal resolution and sustained earnings growth, with risks including litigation outcomes and competitive pressures in the biologics sector.
Nike (NKE) trades at $41.32, down 1.88% on the day, reflecting ongoing investor caution amid revenue declines and margin pressures. Recent earnings beats have not offset concerns over sales weakness in key markets like China. Technical indicators are bearish, with the stock testing support near $41. The company maintains strong brand equity but faces execution risks in its turnaround strategy.
The outlook hinges on Nike's ability to stabilize revenue and improve margins through its 'Win Now' initiatives. Near-term catalysts include the Q4 2026 earnings report on June 30, 2026. Risks include persistent demand softness and competitive pressures, while the consensus price target of $50.45 suggests 22% upside if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Nike Inc
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →
